Verification of association of elevated serum ido enzyme activity with acute rejection and low cd4-atp levels with infection

Transplantation

Volumn 96, Issue 6, 2013, Pages 567-572

  Dharnidharka, Vikas R ^a   Al Khasawneh, Eihab ^a   Gupta, Sushil ^a   Shuster, Jonathan J ^a   Theriaque, Douglas W ^a   Shahlaee, Amir H ^a   Garrett, Timothy J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

IDO; Immuknow; Immune monitoring; Infection; Kidney; Pediatrics; Rejection; Transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRYPTOPHAN;

ACUTE GRAFT REJECTION; ARTICLE; BK VIRUS INFECTION; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; ENZYME ACTIVITY; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; MALE; MASS SPECTROMETRY; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PYELONEPHRITIS; SCHOOL CHILD; VIREMIA;

ACUTE DISEASE; ADENOSINE TRIPHOSPHATE; ADOLESCENT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CHILD; COMMUNICABLE DISEASES; DOWN-REGULATION; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY TRANSPLANTATION; KYNURENINE; LONGITUDINAL STUDIES; MALE; MASS SPECTROMETRY; MONITORING, IMMUNOLOGIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRYPTOPHAN; UP-REGULATION;

EID: 84884817354     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829c7cec     Document Type: Article

References (33)

1. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011; 11: 2228.
2. Dharnidharka VR, Caillard S, Agodoa LY, et al. Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 2006; 81: 1662.
3. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004; 4: 384.
4. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342.
5. Peng W, Chen J, Jiang Y, et al. Urinary fractalkine is a marker of acute rejection. Kidney Int 2008; 74: 1454.
6. Strehlau J, Pavlakis M, Lipman M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A 1997; 94: 695.
7. Billing H, Sander A, Susal C, et al. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients. Transplant Int 2013; 26:331.
8. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77.
9. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006; 82: 663.
10. Batal I, Zeevi A, Heider A, et al. Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol 2008; 129: 587.
11. Dharnidharka V, Gupta S. Viral immune monitoring for posttransplant lymphoproliferative disorder. Pediatr Transplant 2009; 13: 521.
12. Lob S, Konigsrainer A. Role of IDO in organ transplantation: promises and difficulties. Int Rev Immunol 2009; 28: 185.
13. Jia L, Tian P, Ding C. Immunoregulatory effects of indoleamine 2, 3-dioxygenase in transplantation. Transpl Immunol 2009; 21: 18.
14. Brandacher G, Margreiter R, Fuchs D. Clinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and transplantation. Curr Opin Organ Transplant 2008; 13: 10.
15. MulleyWR, Nikolic-Paterson DJ. Indoleamine 2,3-dioxygenase in transplantation. Nephrology (Carlton) 2008; 13: 204.
16. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007; 39: 2167.
17. Ozaki Y, Edelstein MP, Duch DS. The actions of interferon and antiinflammatory agents of induction of indoleamine 2,3-dioxygenase in human peripheral blood monocytes. Biochem Biophys Res Commun 1987; 144: 1147.
18. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5: 2516.
19. Beatty WL, Belanger TA, Desai AA, et al. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun 1994; 62: 3705.
20. Lee GK, Park HJ, Macleod M, et al. Tryptophan deprivation sensitizes activated T cells to apoptosis before cell division. Immunology 2002; 107: 452.
21. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363.
22. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191.
23. Brandacher G, Cakar F, Winkler C, et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007; 71: 60.
24. Dharnidharka VR, Gupta S, Al Khasawneh E, et al. Immune biomarker panel monitoring utilizing IDO enzyme activity and CD4-ATP levels: prediction of acute rejection versus viral replication events. Pediatr Transplant 2011; 15: 321.
25. Lahdou I, Sadeghi M, Daniel V, et al. Increased pretransplantation plasma kynurenine levels do not protect from but predict acute kidney allograft rejection. Hum Immunol 2010; 71: 1067.
26. Yang H, Ding R, Sharma VK, et al. Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts. Transplantation 2007; 83: 1643.
27. Holmes EW, Russell PM, Kinzler GJ, et al. Oxidative tryptophan metabolism in renal allograft recipients: increased kynurenine synthesis is associated with inflammation and OKT3 therapy. Cytokine 1992; 4: 205.
28. Fuchs D, Moller AA, Reibnegger G, et al. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett 1991; 28: 207.
29. Schroecksnadel K, Winkler C, Werner ER, et al. Interferon-gammamediated pathways and in vitro PBMC proliferation in HIV-infected patients. Biol Chem 2009; 390: 115.
30. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2: 32ra6.
31. Murray MF. Insights into therapy: tryptophan oxidation and HIV infection. Sci Transl Med 2010; 2: 32ps23.
32. Sullivan LM, Dukes KA, Losina E. Tutorial in biostatistics. An introduction to hierarchical linear modelling. Stat Med 1999; 18: 855.
33. Shuster JJ, Guo J, Skylar J. Meta-analysis of safety for low event-rate binomial trials. Res Synthesis Methods 2012; 3: 20.